Boston Scientific Corporation (NYSE:BSX): Boosting Its Front Running Portfolio


Dallas, Texas 11/21/2013 (Financialstrend) – Boston Scientific Corporation (NYSE:BSX) is further boosting its front running portfolio of peripheral-embolization technologies. The company has now received United States FDA clearance and the CE Mark approval for Direxion-Torqueable Microcatheter.

Peripheral embolization is the technique that is mainly used by interventional-radiologists in the treatment of liver cancer, uterine-fibroids & other challenging conditions. This involves deliberately-blocking a blood vessel and preventing blood flow to a particular area of the body. This has been proved to be effective in shrinking a tumor / even block an aneurysm.

Professor of Radiology & the director of Interventional-Oncology at Northwestern Memorial Hospital, Riad Salem, M.D., MBA said that the Direxion Microcatheter’s exceptional handling-characteristics are intended to allow physicians to very efficiently access hose difficult-to-navigate vessels in many types of peripheral-embolization procedures

Wednesday’s trading

In Wednesday’s trading session, Boston Scientific Corporation (NYSE:BSX) rose by 0.09%. The opening price of the shares was $12.15, which was the intraday high headed to close at $11.97. Around 9.46M shares were exchanged on Wednesday while the average-volume of 13.74 million shares were traded over a 30 day period. The 52-week low of Boston Scientific Corporation (NYSE:BSX) shares is $5.18 while the 52-week high is $12.48. The company has a market capitalization of $15.98 billion.

About the company

Boston Scientific Corporation (NYSE:BSX) is a company that develops, manufactures and markets medical devices that are utilized in a variety of interventional-medical specialties. In the year that ended 31st December 2011, Boston Scientific Corporation (NYSE:BSX)’s products were up for sale via 7 core businesses: one- Interventional two- Cardiology, three-CRM, four-Endoscopy, five-Peripheral Interventions, six- Urology/Women’s Health, Neuromodulation, and seven- Electrophysiology. In 20111 January, Boston Scientific Corporation (NYSE:BSX) completed acquiring Intelect Medical, Inc. In 2012 June, it acquired Cameron Health, Inc- based in San Clemente, California. From this association, the company added to the existing product portfolio subcutaneous implantable-cardioverter defibrillator.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.